{
    "organizations": [],
    "uuid": "6c471ef3a93f723bd9f97b733300d7cb76a66f60",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-urogen-pharma-announces-positive-i/brief-urogen-pharma-announces-positive-interim-results-from-pivotal-phase-3-olympus-trial-of-ugn-101-idUSASC0A333",
    "ord_in_thread": 0,
    "title": "BRIEF-Urogen Pharma Announces Positive Interim Results From Pivotal Phase 3 Olympus Trial Of UGN-101",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - Urogen Pharma Ltd:\n* UROGEN PHARMA ANNOUNCES POSITIVE INTERIM RESULTS FROM PIVOTAL PHASE 3 OLYMPUS TRIAL OF UGN-101 (MITOGELâ„¢) FOR NON-SURGICAL TREATMENT OF UPPER TRACT UROTHELIAL CANCER (UTUC)\n* UROGEN PHARMA LTD - INTERIM RESULTS SHOWED COMPLETE RESPONSE (CR) RATE OF 59 PERCENT IN PATIENTS WITH LOW-GRADE UTUC\n* UROGEN PHARMA LTD - OLYMPUS TRIAL CONTINUES TO ENROLL PATIENTS, AND TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2018\n* UROGEN PHARMA LTD - CRS TO DATE REMAIN DURABLE AT THREE, SIX AND NINE-MONTH FOLLOW-UP IN PHASE 3 OLYMPUS TRIAL OF UGN-101\n* UROGEN PHARMA LTD - UGN-101 APPEARED TO BE WELL-TOLERATED WITH MOST TREATMENT-EMERGENT ADVERSE EVENTS CHARACTERIZED AS MILD OR MODERATE AND TRANSIENT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-22T03:23:00.000+03:00",
    "crawled": "2018-05-22T19:27:13.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "urogen",
        "pharma",
        "ltd",
        "urogen",
        "pharma",
        "announces",
        "positive",
        "interim",
        "result",
        "pivotal",
        "phase",
        "olympus",
        "trial",
        "treatment",
        "upper",
        "tract",
        "urothelial",
        "cancer",
        "utuc",
        "urogen",
        "pharma",
        "ltd",
        "interim",
        "result",
        "showed",
        "complete",
        "response",
        "cr",
        "rate",
        "percent",
        "patient",
        "utuc",
        "urogen",
        "pharma",
        "ltd",
        "olympus",
        "trial",
        "continues",
        "enroll",
        "patient",
        "result",
        "expected",
        "second",
        "half",
        "urogen",
        "pharma",
        "ltd",
        "cr",
        "date",
        "remain",
        "durable",
        "three",
        "six",
        "phase",
        "olympus",
        "trial",
        "urogen",
        "pharma",
        "ltd",
        "appeared",
        "adverse",
        "event",
        "characterized",
        "mild",
        "moderate",
        "transient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}